NBI-1117569

NBI-1117569 is an investigational, orally administered small molecule drug that acts as a selective agonist of the muscarinic acetylcholine receptor M4 (M4-preferring agonist). It was discovered by Nxera Pharma (formerly Sosei Heptares) using their structure-based drug design platform and is being developed in partnership with Neurocrine Biosciences. The compound is currently in Phase 1 clinical trials for neurological and neuropsychiatric conditions, including psychosis and cognitive disorders. By selectively activating the M4 muscarinic receptor, NBI-1117569 aims to modulate neurotransmission relevant to diseases such as schizophrenia, dementia, Parkinson’s disease-related psychosis, and other psychiatric or cognitive disorders[1][4][5][7][9].